During the last several months, multiple manufacturers have joined the ‘COVID-19 vaccine club’. Now it’s time for a company from China to bring extra hope to the people. The country where SARS-CoV-2 has its origin approved its first vaccine for the coronavirus.
Sinopharm is the company in question, and it developed the first COVID-19 vaccine from China. Npr.com writes that medical products agency has given market approval for the drug. Clinical studies for the vaccine were conducted in China as well as in other countries like Egypt, Jordan, Peru, the United Arab Emirates, Bahrain, Argentina and Morocco.
79% efficacy rate for Sinopharm’s vaccine
With 79% efficacy rate, the Sinopharm vaccine is much less effective than those developed by Pfizer/BioNTech and Moderna (about 95% efficacy rate for both). However, the approval is conditional, as it is needed for Sinopharm to continue collecting data about the long-term effects of the vaccine.
John Ruwitch from NPR declared:
During the summer, Beijing gave a green light for emergency use of the Sinopharm vaccine and several others,
State media say that millions of doses have already been administered, including to front-line medical staff and people going abroad for work. Emergency use is set to expand.
While Pfizer and Moderna’s vaccines use a revolutionary platform based on genes, the Sinopharm drug uses inactivated coronavirus for causing the body to produce antibodies. A great resemblance between all three vaccines is that they all need two injections for the same person in order to be fully effective.
The Sinopharm subsidiary known as the China National Biotec Group (CNBG) is responsible for creating China’s vaccine for COVID-19. Luckily enough, the Asian country is barely reporting any daily cases of COVID-19 infections, although that’s where the disease first erupted. China is currently on the 81st place in the worldometers.info’s pandemic ranking.